Analyzing Oncocyte (IMDX) and Its Rivals

Oncocyte (NASDAQ:IMDX) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Oncocyte to similar companies based on the strength of its earnings, analyst recommendations, risk, institutional ownership, dividends, profitability and valuation.

Profitability

This table compares Oncocyte and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-12,359.35%	-203.09%	-30.93%

Valuation and Earnings

This table compares Oncocyte and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-1.60
Oncocyte Competitors	$698.13 million	$10.43 million	-15.34

Oncocyte’s peers have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Oncocyte has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Oncocyte’s peers have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Oncocyte and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9847	15134	45521	1589	2.54

Oncocyte presently has a consensus target price of $10.50, indicating a potential upside of 339.33%. As a group, “Biotechnology” companies have a potential upside of 99.72%. Given Oncocyte’s higher probable upside, research analysts plainly believe Oncocyte is more favorable than its peers.

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Oncocyte beats its peers on 7 of the 13 factors compared.

Oncocyte Company Profile

Oncocyte Corporation is a molecular diagnostics company focused on developing tests that support cancer diagnosis, treatment decisions, and transplant monitoring. Its technologies are designed to help physicians assess disease characteristics and make more informed clinical decisions. The company has developed oncology products including DetermaDx, a genomic test intended to help evaluate the malignancy risk of lung nodules, and DetermaRx, which is designed to identify lung cancer patients who may face a higher risk of recurrence.